Experimental intravenous cell therapy of acute and chronic renal failure

Abstract

The therapeutic effect of intravenous injection of human fetal bone marrow mesenchymal stem cells or summary culture of kidney cells were studied on models of chronic or acute renal failure in outbred albino rats. Both cell types promoted improvement and normalization of the renal function in rats with stable chronic renal insufficiency (2 weeks after kidney cell injection, 1 month after bone marrow mesenchymal stem cell injection). Renal function remained normal or subnormal during the delayed period (3-3.5 months after injection). In rats with latent stage of chronic renal insufficiency, exacerbation was induced by additional 40-min ischemia. All rats receiving intravenous injection of saline died. Improvement of the functional parameters started 2 weeks after injection of kidney cells or bone marrow mesenchymal stem cells, and normalization was observed after 1.1-5 months. During the delayed period (after 3-4 months), functional parameters retained at normal or subnormal levels. In experimental series III, all rats with acute renal failure intravenously injected with saline (control) died from uremia on days 2-4. After injection of kidney cells 50% rats survived and renal function in these animals returned to normal after 2 weeks. After injection of bone marrow mesenchymal stem cells 83% rats survived, functional parameters returned to normal after 3 weeks.

Isolation, Characterization, and Expansion Methods for Defined Primary Renal Cell Populations from Rodent, Canine, and Human Normal and Diseased Kidneys

“…In a rodent model, chronic renal disease was established by heminephrectomy and ischemia to the intact kidney. 11 Injection of a heterogeneous mixture of human fetal kidney cells, containing embryonic tubular cells, via the vena cava into rats with established disease led to transient improvement of all functional parameters. The recovery observed in rats receiving fetal kidney cells was more rapid in the context of chronic disease state than that observed in rats receiving bone marrow-derived mesenchymal stem cells.…”

Transplantation of amniotic membrane‐derived multipotent cells ameliorates and delays the progression of chronic kidney disease in cats

“…Previous studies of MSC application in rodent model of induced CKD reported renal function improvement through intrarenal fibrosis and inflammation reduction (Cavaglieri et al., ; Kirpatovskii et al., ; Lee et al., ; Ninichuk et al., ; Semedo et al., ; Villanueva et al., , ; Wang, He, Pei, & Zhao, ). Our findings are as satisfactory as those found in rodent model of induced CKD; however, despite using MSCs with similar therapeutic potential, findings in previous studies in cats with naturally occurring CKD did not report significant variations (Quimby et al., , , ).…”

“…The potential MSC therapy for CKD has been reported in numerous studies of induced CKD in rodents (Cavaglieri, Martini, Sogayar, & Noronha, ; Kirpatovskii et al., ; Lee et al., ; Ninichuk et al., ; Semedo et al., ; Villanueva et al., , ). These studies have shown a decrease and stabilization of the clinical condition, evidenced by renal function improvement and by inflammation and renal fibrosis reduction (Cavaglieri et al., ; Lee et al., ; Ninichuk et al., ; Semedo et al., ; Villanueva et al., ).…”

Priming of Mesenchymal Stem Cells with Oxytocin Enhances the Cardiac Repair in Ischemia/Reperfusion Injury

“…10 5 stem cells and demonstrated that a small cell number with oxytocin pretreatment could be enough to exert its therapeutic effect for 4 weeks in a myocardial infarction rat model. Antifibrotic, anti-inflammatory, and proangiogenic effects are well-known therapeutic mechanisms of stem cells in ischemic-injured organs [Kirpatovskii et al, 2007;Segers and Lee, 2008]. MSCs differentiated into myogenic, endothelial, and smooth muscle cells in the infarcted reveal whether the transient induction might trigger an unknown signaling cascade.…”